Mark Lemmon is the Alfred Gilman Professor of Pharmacology at the Yale University School of Medicine, Deputy Director of Yale Cancer Center, and Co-Director of the Yale Cancer Biology Institute. His research combines biochemistry and structural biology with cell biology, focusing on understanding molecular mechanisms of transmembrane signaling by cell-surface growth factor receptors such as the epidermal growth factor (EGF) receptor.
Mark has made important contributions to the discovery of both normal and pathological activation mechanisms of growth factor receptors and the signaling networks that they engage within cells. He is also committed to exploiting this understanding clinically. These receptors and their downstream effectors are activated aberrantly in numerous cancers, and are important targets of cancer drugs. Mark's recent work has focused on the need to understand the biochemistry of oncogenic activation to use such drugs effectively.
Before moving to Yale, Dr. Lemmon was George W. Raiziss Professor and Chair of Biochemistry and Biophysics at the University of Pennsylvania Perelman School of Medicine. He received his bachelor's degree in Biochemistry from Hertford College, Oxford, and his Ph.D. from Yale University.
Professional position
- Alfred Gilman Chair of Pharmacology, Department of Pharmacology, Yale University
- Co-Director, Cancer Biology Institute, Yale University
Subject groups
-
Astronomy and Physics
Crystallography, Biophysics
-
Chemistry
Chemistry, biological
-
Molecules of Life
Biochemistry and molecular biology, Biophysics and structural biology, Cell biology (incl molecular cell biology)
-
Health and Human Sciences
Molecular medicine
